| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Department of Pediatrics, Vanderbilt University, Nashville, TN 37232; and
Respiratory Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892
A respiratory syncytial virus (RSV) vaccine will need to be administered by 1 mo of age to protect young infants; therefore, it will need to be effective in the presence of maternally acquired RSV Abs. In the present study, the immunogenicity and efficacy of two live attenuated RSV vaccine candidates of different level of attenuation were evaluated in mice passively immunized with varying quantities of RSV Abs. The replication of the RSV vaccines was suppressed in the lower, but not the upper, respiratory tract of the passively immunized mice. Immunization with either vaccine candidate was highly efficacious against challenge with wild-type RSV in both passively immunized and control mice. Nonetheless, a high level of immunity was seen even in passively/actively immunized animals that failed to develop a humoral immune response, suggesting that T cells mediated the immunity. Depletion of CD4+ and CD8+ T cells in passively/actively immunized and control animals at the time of challenge with wild-type RSV demonstrated that CD4+ and CD8+ T cells made significant independent contributions to the restriction of replication of RSV challenge virus in both the upper and lower respiratory tracts. Although passively acquired serum RSV Abs suppressed the primary systemic and mucosal Ab responses of IgM, IgG, and IgA isotypes, B lymphocytes were nevertheless primed for robust secondary Ab responses. Thus, immunity mediated by CD4+ and CD8+ T cells and Abs can be readily induced in mice by live RSV vaccine candidates in the presence of physiologic levels of RSV neutralizing Abs.
This article has been cited by other articles:
|
|
 |
|
  W. Zhang and R. A. Tripp RNA Interference Inhibits Respiratory Syncytial Virus Replication and Disease Pathogenesis without Inhibiting Priming of the Memory Immune Response J. Virol., December 15, 2008; 82(24): 12221 - 12231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Mok, S. J. Tollefson, A. B. Podsiad, B. E. Shepherd, V. V. Polosukhin, R. E. Johnston, J. V. Williams, and J. E. Crowe Jr An Alphavirus Replicon-Based Human Metapneumovirus Vaccine Is Immunogenic and Protective in Mice and Cotton Rats J. Virol., November 15, 2008; 82(22): 11410 - 11418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. L. Collins and B. S. Graham Viral and Host Factors in Human Respiratory Syncytial Virus Pathogenesis J. Virol., March 1, 2008; 82(5): 2040 - 2055. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Fouchet, S. Marchandeau, N. Bahi-Jaber, and D. Pontier The role of maternal antibodies in the emergence of severe disease as a result of fragmentation J R Soc Interface, June 22, 2007; 4(14): 479 - 489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bukreyev, M. H. Skiadopoulos, B. R. Murphy, and P. L. Collins Nonsegmented negative-strand viruses as vaccine vectors. J. Virol., November 1, 2006; 80(21): 10293 - 10306. [Full Text] [PDF]
|
|
|
|
 |
|
 P. G. Thomas, S. A. Brown, W. Yue, J. So, R. J. Webby, and P. C. Doherty An unexpected antibody response to an engineered influenza virus modifies CD8+ T cell responses PNAS, February 21, 2006; 103(8): 2764 - 2769. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. L. Collins and B. R. Murphy New Generation Live Vaccines against Human Respiratory Syncytial Virus Designed by Reverse Genetics Proceedings of the ATS, August 1, 2005; 2(2): 166 - 173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Mrusek, S. Vallbracht, and S. Ehl The impact of splenectomy on antiviral T cell memory in mice Int. Immunol., January 1, 2005; 17(1): 27 - 33. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
